Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection
NCT01239095 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2023-02-22
Summary
Colorectal cancer is the third most common form of cancer found in the United States. To date surgical resection provides the best chance for cure. Unfortunately, despite "curative" surgery, tumor recurrences develop in 30-40% of patients from either unforeseen residual metastases or from viable tumor cells shed into the circulation before or at the time of surgery. There is evidence from both humans and mice suggesting that tumor growth is stimulated after surgery for a period of time.
This study calls for the administration of a green tea extract and a milk thistle extract, two orally ingested supplements, during the week immediately before and weeks after your surgery. It is not the current standard of care to give anti-cancer drugs during the perioperative period. The basic idea behind this study is that it should be beneficial to inhibit cancer growth in the days leading up to and following surgery. Why is this the case?
It makes sense to limit or inhibit tumor growth before surgery with drugs provided it can be done safely and does not interfere with the surgery. It is also logical to give anti-cancer drugs after surgery because, unfortunately, about 35 percent of colorectal cancer patients, after resection, have hidden tumor cells that remain in the body. There is also strong human evidence that tumor growth is stimulated during the first month after tumor resection as a result of the surgical injuries and the healing process. Therefore, there is good reason to give anti-cancer drugs as soon as possible after surgery in order to offset some of surgery's negative effects.
Although both supplements have been given safely to a wide variety of patients with a number of different medical problems, the two supplements together have never been given to cancer patients during the weeks just before and following surgery. The researchers hypothesize that the administration of these two supplements together will be safe in the period surrounding colorectal cancer surgery.
Conditions
Interventions
- DRUG
-
Green Tea and Milk Thistle Supplements
Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
Sponsors & Collaborators
-
St. Luke's-Roosevelt Hospital Center
collaborator OTHER -
Richard Whelan
lead OTHER
Principal Investigators
-
Richard L Whelan, MD · Mount Sinai St. Luke's Roosevelt Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-07-31
- Primary Completion
- 2023-02-28
- Completion
- 2023-02-28
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal Surgery
NCT00973869 ·Status: UNKNOWN ·Phase: PHASE1
-
Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
NCT01934179 ·Status: TERMINATED
-
DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements
NCT00550563 ·Status: COMPLETED ·Phase: NA
-
Prebiotics in Rectal Cancer
NCT05516641 ·Status: UNKNOWN ·Phase: NA
-
Curcumin for the Prevention of Colon Cancer
NCT00027495 ·Status: COMPLETED ·Phase: PHASE1
-
Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates
NCT01214681 ·Status: UNKNOWN ·Phase: NA
-
Dietary Supplement on the Intestinal Microbiota in Patients with Colon Cancer
NCT05472753 ·Status: COMPLETED ·Phase: NA
-
High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed
NCT00002650 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors
NCT05136092 ·Status: COMPLETED ·Phase: NA
-
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer
NCT05131243 ·Status: UNKNOWN ·Phase: NA
-
Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma
NCT01948661 ·Status: COMPLETED ·Phase: NA
-
FOcUs on Colorectal CAncer oUtcomes: Long-Term Study
NCT03965325 ·Status: COMPLETED
-
Do Patients With Colorectal Cancer Understand That Their Family is at Risk?
NCT00145860 ·Status: TERMINATED
-
Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer
NCT04812912 ·Status: RECRUITING
-
Curcumin Biomarkers
NCT01333917 ·Status: COMPLETED ·Phase: PHASE1
-
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
NCT00966667 ·Status: COMPLETED
-
The Sexual Health of Rectal Cancer Patients
NCT00712751 ·Status: COMPLETED
-
Presence of Circulating Tumor DNA in Colorectal Cancer
NCT01198743 ·Status: COMPLETED
-
Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer
NCT04832763 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Immune Response in Peripheral Blood of Patients With Colon Cancer
NCT00900432 ·Status: COMPLETED
-
Mycotoxin Exposure and Dietary Habits in Colorectal Cancer Prevention and Development Among Polish Population
NCT04152265 ·Status: UNKNOWN ·Phase: NA
-
Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan
NCT00172757 ·Status: UNKNOWN
-
Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers
NCT00410579 ·Status: COMPLETED
-
Quality of Life in Colorectal Cancer Survivors
NCT03521765 ·Status: COMPLETED ·Phase: NA
-
Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer
NCT00625625 ·Status: UNKNOWN ·Phase: PHASE2